Market Place
Sourcing Support
BioAtla Announces Registered Direct Offering For Clinical Programs
20 Dec 2024 //
GLOBENEWSWIRE
BioAtla to Present Poster at IASLC 2024 Hot Topic Meeting
10 Dec 2024 //
GLOBENEWSWIRE
BioAtla Reports Q3 2024 Financial Results & Highlights Progress
07 Nov 2024 //
GLOBENEWSWIRE
BioAtla to Report Q3 2024 Results on Nov 7, 2024
31 Oct 2024 //
GLOBENEWSWIRE
BioAtla Announces Poster At SITC Annual Meeting
04 Oct 2024 //
GLOBENEWSWIRE
BioAtla Announces Oral Presentation at Melanoma Research Congress
01 Oct 2024 //
GLOBENEWSWIRE
BioAtla Context License BA3362 Nectin-4 x CD3 T Cell Antibody
23 Sep 2024 //
GLOBENEWSWIRE
BioAtla Presented Ozuriftamab Vedotin Data At ESMO 2024
16 Sep 2024 //
GLOBENEWSWIRE
BioAtla Announces Poster Presentation At ESMO Meeting
09 Sep 2024 //
GLOBENEWSWIRE
BioAtla To Participate In H.C. Wainwright Conference
28 Aug 2024 //
GLOBENEWSWIRE
Bioatla Reports Q2 2024 Results And Recent Progress
08 Aug 2024 //
GLOBENEWSWIRE
BioAtla To Announce Q2 2024 Results On August 8
01 Aug 2024 //
GLOBENEWSWIRE
BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day
25 Jul 2024 //
GLOBENEWSWIRE
BioAtla`s Ozuriftamab Vedotin Gets FDA Fast Track For Head And Neck Cancer
23 Jul 2024 //
GLOBENEWSWIRE
BioAtla to Host Virtual R&D Day on Clinical Program & Pipeline July 25, 2024
27 Jun 2024 //
GLOBENEWSWIRE
BioAtla to Participate in the Jefferies Global Healthcare Conference
29 May 2024 //
GLOBENEWSWIRE
Bioatla Phase 1 Evalstotug: Clinical Benefit At 2024 Asco Shown
23 May 2024 //
GLOBENEWSWIRE
BioAtla Reports Q1 2024 Results, Progress Highlights
14 May 2024 //
GLOBENEWSWIRE
BioAtla to Participate in the Citizens JMP Life Sciences Conference
08 May 2024 //
GLOBENEWSWIRE
BioAtla To Announce Q1 2024 Results And Highlights On May 14
07 May 2024 //
GLOBENEWSWIRE
BioAtla Gets FDA IND Clearance For Anti-Nectin-4 ADC BA3361
06 May 2024 //
GLOBENEWSWIRE
BioAtla to Present Poster at ASCO 2024 Annual Meeting
24 Apr 2024 //
GLOBENEWSWIRE
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results
26 Mar 2024 //
GLOBENEWSWIRE
BioAtla to Announce Fourth Quarter & Full-Year 2023 Financial Results
19 Mar 2024 //
GLOBENEWSWIRE
BioAtla Announces Poster Presentations at the 2024 AACR Annual Meeting
07 Mar 2024 //
GLOBENEWSWIRE
BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
20 Dec 2023 //
GLOBENEWSWIRE
BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data
13 Dec 2023 //
GLOBENEWSWIRE
BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data
06 Dec 2023 //
GLOBENEWSWIRE
BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023
05 Dec 2023 //
GLOBENEWSWIRE
BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC
28 Nov 2023 //
GLOBENEWSWIRE
BioAtla Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
BioAtla™s Jay M. Short Selected for The Explorers Club Lowell Thomas Award
12 Oct 2023 //
GLOBENEWSWIRE
BioAtla Provides Third Quarter 2023 Financial Results
10 Oct 2023 //
GLOBENEWSWIRE
BioAtla to Participate in H.C. Wainwright 25th Annual Global Conference
06 Sep 2023 //
GLOBENEWSWIRE
BioAtla to Participate in Upcoming Investor Conferences in August
03 Aug 2023 //
GLOBENEWSWIRE
BioAtla Reports Second Quarter 2023 Financial Results
01 Aug 2023 //
GLOBENEWSWIRE
BioAtla to Announce Second Quarter 2023 Financial Results
25 Jul 2023 //
GLOBENEWSWIRE
BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index
26 Jun 2023 //
GLOBENEWSWIRE
BioAtla to Participate in the Jefferies Healthcare Conference
31 May 2023 //
GLOBENEWSWIRE
BioAtla Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
BioAtla to Announce 1Q 2023 FYR and Provide Business Highlights on May 11, 2023
04 May 2023 //
GLOBENEWSWIRE
BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results
23 Mar 2023 //
GLOBENEWSWIRE
BioAtla to Announce Fourth Quarter and Full-Year 2022 Financial Results
16 Mar 2023 //
GLOBENEWSWIRE
BioAtla Announces Change in Executive Leadership
27 Feb 2023 //
GLOBENEWSWIRE
BioAtla Announces FDA Clearance of Investigational NDA for BA3182
23 Feb 2023 //
GLOBENEWSWIRE
BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones
10 Jan 2023 //
GLOBENEWSWIRE
Viatris Announces Appointments of Scott A. Smith and Elisha W. Finney BOD
30 Dec 2022 //
PR NEWSWIRE
BioAtla to Participate in the 41st Annual J.P. Morgan Healthcare Conference
22 Dec 2022 //
GLOBENEWSWIRE
BioAtla to Participate in the Jefferies London Healthcare Conference
08 Nov 2022 //
PRESS RELEASE
BioAtla Announces $65 Million Underwritten Offering of its Common Stock
04 Nov 2022 //
GLOBENEWSWIRE
BioAtla Reports 3Q FYR and Highlights Recent Progress
03 Nov 2022 //
GLOBENEWSWIRE
BioAtla to Announce Third Quarter 2022 Financial Results
27 Oct 2022 //
GLOBENEWSWIRE
BioAtla Reports Q2 2022 Financial Results And Highlights Recent Progress
09 Aug 2022 //
GLOBENEWSWIRE
BioAtla to Participate in the 2022 BTIG Biotechnology Conference
03 Aug 2022 //
PRESS RELEASE
BioAtla to Announce Second Quarter 2022 Financial Results
02 Aug 2022 //
GLOBENEWSWIRE
BioAtla to Participate in 2022 Jefferies Global Healthcare Conference
01 Jun 2022 //
GLOBENEWSWIRE
BioAtla Reports Q1 2022 Financial Results and Highlights Recent Progress
04 May 2022 //
GLOBENEWSWIRE
BioAtla to Announce Q1 2022 Financial Results
08 Apr 2022 //
GLOBENEWSWIRE
BioAtla, BMS Collaborate for BA3011 & BA302 with Opdivo in Solid Tumors
10 Jan 2022 //
PRNEWSWIRE
BioAtla Announces Q1 2021 Financial Results And Provides Business Update
12 May 2021 //
PRNEWSWIRE
